CIL Announces Breakthrough in Benzene Recovery, Addressing Cost, Environmental, and Supply Challenges for OLED Display Manufacturers
TEWKSBURY, MA / ACCESSWIRE / December 12, 2024 / Cambridge Isotope Laboratories, Inc. (CIL) has successfully developed and implemented a game-changing benzene-d6 recovery program, addressing major pain points for manufacturers of organic light-emitting diode (OLED) displays. This innovative service reduces costs, minimizes environmental impact, and conserves scarce deuterium supplies.
OLED display producers rely heavily on deuterated benzene (benzene-d6) as a critical starting material in their synthesis processes. However, this results in significant quantities of depleted benzene-d6, which is no longer usable but still retains considerable deuterium value. The disposal of such depleted material poses environmental challenges and substantial expenses.
CIL's benzene-recovery program offers a transformative solution. Customers can now return their depleted benzene-d6 to CIL, where it undergoes a proprietary re-enrichment process to restore it to virgin material quality. This service is available at a significant cost savings compared to new benzene-d6, providing significant economic benefits.
Beyond the financial advantages, the program has far-reaching environmental and supply implications. It eliminates the need for costly disposal, reduces the demand on increasingly scarce deuterium (derived from heavy water, D2O) and conserves this vital resource for its growing applications in science, medical diagnostics, pharmaceuticals, and semiconductor production.
Recycling offers several sustainable benefits. It reduces pollution by releasing fewer chemicals into the environment. Recycling also saves energy, as reprocessing chemicals like benzene requires less energy than producing them from raw materials. This leads to lower greenhouse gas emissions, helping to combat climate change.
"This initiative underscores CIL's commitment to collaboration and innovation in addressing our customers' most pressing challenges," said Cliff Caldwell, CEO of CIL. "By recovering and re-enriching depleted benzene-d6, we create a circular economy approach that is both economically and environmentally sustainable. As the world's largest supplier of benzene-d6, we are uniquely positioned to deliver this groundbreaking service."
CIL's benzene recovery program is the result of 12 months of dedicated development, expansion, and rigorous testing to ensure reliable capacity and uncompromising quality. CIL invites interested parties to inquire about the program's details and how to participate.
About Cambridge Isotope Laboratories, Inc.
CIL is the world's largest manufacturer and global supplier of stable isotopes and stable isotope-labeled compounds used in research, environmental, pharmaceutical, medical diagnostic, OLED, and industrial markets. CIL subsidiary ABX, located in Dresden, Germany, is active in the development and commercialization of radio isotopic-labeled compounds for the diagnosis and treatment of cancers. CIL is an operating business owned by Otsuka Pharmaceutical. The CIL business consists of two facilities in the Boston, MA, area; a large isotope-enrichment production plant in Xenia, OH; CIL China; CIL Canada; ABX in Dresden, Germany; and Eurisotop in Saclay, France. For more information on CIL, visit isotope.com.
Contact Information
Crissy Krisko
crissyk@isotope.com
1.978.269.1930
SOURCE: Cambridge Isotope Laboratories, Inc.
View the original press release on accesswire.com
Cambridge Isotope Laboratories, Inc.
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
RE Royalties Announces Annual Grant of Stock Options and Restricted Share Units20.1.2026 00:00:00 CET | Press release
All amounts in Canadian dollars unless otherwise stated VANCOUVER, BC / ACCESS Newswire / January 19, 2026 / RE Royalties Ltd. (TSXV:RE)(OTCQX:RROYF)(FSE:Y2V) ("RE Royalties" or the "Company") is pleased to announce that, as part of the Company's annual compensation review, the Board of Directors have authorized the grant of 1,195,000 stock options (the "Options") to directors, officers, employees and consultants of the Company. The Options have an exercise price of CAD $0.30 per share and are exercisable for a period of three-years from the date of grant. The Options were granted in accordance with the Company's Stock Option Plan. In addition, the Board of Directors have authorized the grant of an aggregate 800,000 restricted share units ("RSUs") to officers, employees and consultants of the Company. The RSUs were granted in accordance with the Company's RSU Plan in place. "We are pleased to provide these incentive-based equity awards to our valued team members," said Bernard Tan, CEO
GA-ASI and Barzan Holdings Sign MOU19.1.2026 18:00:00 CET | Press release
Companies Will Collaborate on the Development of Advanced Battle Management DOHA, QA / ACCESS Newswire / January 19, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) -- the world leader in unmanned systems - and Barzan Holdings, Qatar's national defence and security leader, signed a Memorandum of Understanding (MOU) to collaborate on the development of advanced Battle Management software capabilities. The signing took place on Monday during the Doha International Maritime Defence Exhibition and Conference (DIMDEX). The MOU provides a framework for cooperation between GA-ASI, GA-Intelligence, and Barzan Holdings to develop software solutions that enhance theater-level situational awareness and enable the efficient processing, correlation, and dissemination of intelligence. These capabilities are intended to support faster, higher-quality decision-making in complex, multi-domain operational environments. For General Atomics, the agreement underscores the strategic importance of
GA-ASI Makes Another Autonomous Aerial Intercept in Company-Funded Demo with MQ-20 Avenger(R)19.1.2026 03:00:00 CET | Press release
SAN DIEGO, CALIFORNIA / ACCESS Newswire / January 18, 2026 / In its latest demonstration of advanced autonomy development, General Atomics Aeronautical Systems, Inc. (GA-ASI) successfully executed a mission autonomy flight using its MQ-20 Avenger® jet equipped with the latest government reference autonomy software. The test included a live engagement between the MQ-20 and an aggressor aircraft flown by an onboard human pilot, highlighting the advanced maturity of autonomous systems, seamless integration of mission elements, and the ability of autonomy to leverage onboard sensors to make independent decisions and execute complex tasks. GA-ASI's Avenger jet has served as a surrogate for Collaborative Combat Aircraft (CCA) for more than five years, both before and since the arrival of GA-ASI's purpose-built XQ-67A and YFQ-42A aircraft. The recent Avenger demo began with planning in the Human-Machine Interface (HMI), followed by loading the mission profile onto the MQ-20. Once airborne, th
GoodData Accelerates in Q4 with Product Innovation and Business Growth15.1.2026 10:55:00 CET | Press release
SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / January 15, 2026 / GoodData, a leading AI-native decision intelligence platform, today announced strong Q4 results driven by record product development velocity, the launch of its Intelligence Layer for trustworthy AI, and continued expansion across the financial services sector. The quarter underscored GoodData's commitment to delivering inclusive, governed AI at scale, marked by significant accessibility milestones and sustained adoption among global enterprises. Business highlights GoodData's momentum accelerated throughout Q4, fuelled by a surge in development activity and deepening strategic partnerships. The company delivered a 50% year-on-year increase of product releases in Q4 2025 compared to Q4 2024, with a three-fold increase in AI-focused development activity in agentic workflows in H2. "Our performance in Q4 shows that speed and trust are not mutually exclusive," said Roman Stanek, CEO and Founder of GoodData. "With the launch
A True Empowerer - AGFA HealthCare Radiates Imaging Innovation at ECR 202615.1.2026 09:00:00 CET | Press release
In Vienna, Enterprise Imaging offers the "Clinician-First" approach to keeping radiologists in their flow, spotlighting the human behind the innovation and empowering them to work in comfort with their technology. MORTSEL, BE / ACCESS Newswire / January 15, 2026 / At ECR 2026, AGFA HealthCare will unveil its latest imaging innovations that transform the clinician experience and drive smarter care. Turning knowledge into action, AGFA delivers advancements which empower radiologists with seamless workflows, intelligent automation and tailored diagnostic environments. Under the event 2026 theme "Rays of Knowledge", AGFA is ready to demonstrate how we have reached the summit of Empowerer - adopting the ‘Clinician-First' approach, which demonstrates a profound understanding of the clinician's challenges and workflow realities. "Clinician First is more than a message - it's a mindset", says Andrea Polticchia, Regional President for Southern Europe, AGFA HealthCare. "This approach reflects ou
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom